Comparative Pharmacology
Head-to-head clinical analysis: QTERN versus TRIJARDY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QTERN versus TRIJARDY XR.
QTERN vs TRIJARDY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QTERN is a fixed-dose combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Dapagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin increases incretin hormones, enhancing insulin secretion and decreasing glucagon levels.
TRIJARDY XR is a fixed-dose combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin, a biguanide. Empagliflozin reduces renal glucose reabsorption by inhibiting SGLT2 in the proximal tubule, increasing urinary glucose excretion. Metformin decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
One tablet orally twice daily; each tablet contains dapagliflozin 10 mg and saxagliptin 5 mg.
Empagliflozin 5 mg / linagliptin 5 mg / metformin extended-release 1000 mg orally twice daily with meals; initial dose based on current regimen, titrate gradually.
None Documented
None Documented
Terminal half-life approximately 5 hours; supports twice-daily dosing.
Empagliflozin: terminal t1/2 ~12.4 h; linagliptin: terminal t1/2 ~12-24 h (effective t1/2 due to long DPP-4 binding); metformin: terminal t1/2 ~6.2 h (prolonged in renal impairment, up to 18 h).
Fecal (59% unchanged) and renal (42% unchanged, primarily via tubular secretion).
Renal: empagliflozin ~54% unchanged, linagliptin ~5% unchanged, metformin ~90% unchanged; fecal: empagliflozin ~41% (mostly unchanged), linagliptin ~80% (mostly unchanged), metformin minimal.
Category C
Category C
Antidiabetic Combination
Antidiabetic Combination